GlassScriptPhysician profile
Odise Cenaj
NPI 1063845550
$532.31
in general payments reported to CMS, 2019-2025
10 companies · $23.82 in 2025
The $23.82 reported for 2025 was less than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.44 · 2021: $162 · 2022: $47.43 · 2023: $105 · 2024: $181 · 2025: $23.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.87 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $118.50 | 2023-2024 | Enhertu |
| Amgen INC. | $104.44 | 2021-2023 | Lumakras |
| Redhill Biopharma INC. | $79.85 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $66.50 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.65 | 2021 | |
| Abbvie INC. | $28.44 | 2020-2021 | |
| Hologic Sales and Service, LLC | $28.10 | 2024 | Aptima |
| Ardelyx, INC. | $20.30 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $20.07 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.46 | 2023 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odise Cenaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.